Research To Practice | Oncology Videos

Latest Episodes:

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of RET Fusion-Positive Non-Small Cell Lung Cancer (Companion Video Lecture) Oct 25, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Justin Gainor, including the following topics:

Biology of RET Genetic Alterations in Cancer (0:00)
Early Efforts to Target RET Alterations in Non-Small Cell Lung Cancer (NSCLC) (1:44)
Mechanisms of Action of Selective RET Inhibitors (3:58)
Clinical Trial Evidence Supporting Selpercatinib Therapy for RET-Altered NSCLC (5:04)
Updated Efficacy and Safety Results with Pralsetinib Therapy for RET-Altered NSCLC (13:14)
Mechanisms of Resistance to Selective RET Inhibitors (19:33)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of RET Fusion-Positive Non-Small Cell Lung Cancer Oct 25, 2022

Show notes

Featuring an interview with Dr Justin Gainor, including the following topics:

Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00)
Significance of non-fusion RET abnormalities in NSCLC (3:33)
Clinical impact of tumor-agnostic targeted therapy (5:11)
Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46)
Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24)
Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45)
Adjuvant therapy for RET-rearranged NSCLC (26:23)
Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07)
Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40)
Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28)

CME information and select publications

Breast Cancer | Meet The Professor: Optimizing the Management of HER2-Positive Breast Cancer — Part 2 Oct 21, 2022

Show notes

Featuring perspectives from Dr Nancy Lin, including the following topics:

Introduction: Journal Club with Nancy U Lin, MD (0:00)
Case: A woman in her late 60s with ER-positive, HER2-positive breast cancer who has significant neuropathy and develops liver metastases after adjuvant docetaxel/carboplatin/trastuzumab — Laurie Matt-Amaral, MD, MPH (15:30)
Case: A woman in her late 80s with weakly ER-positive, PR-negative, HER2-positive, gBRCA2 mutation-positive T2N1M0 breast cancer after neoadjuvant paclitaxel/trastuzumab — Zanetta S Lamar, MD (20:16)
Case: A woman in her early 50s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) with progressive brain metastases after T-DM1 and whole braid radiation therapy — Justin Peter Favaro, MD, PhD (31:06)
Case: A woman in her late 40s with triple-positive breast cancer after resection of brain metastasis — Shaachi Gupta, MD, MPH (37:26)
Case: A woman in her mid 60s with ER/PR-positive, HER2-low mBC after endocrine therapy-based treatments, capecitabine — Vignesh Narayanan, MD (46:44)
Case: A woman in her early 60s with progressive triple-positive mBC receiving T-DXd — Joseph Martins, MD (54:36)

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer Oct 20, 2022

Show notes

Featuring an interview with Prof Sia Daneshmand, including the following topics:

Clinical presentation and initial evaluation of non-muscle-invasive urothelial bladder cancer (NMIBC) (0:00)
Alternative induction regimens when BCG is not available (4:06)
Treatment options for patients with BCG-refractory disease (8:46)
Role of immunotherapy in treating NMIBC (13:58)
Role of cystectomy in treating NMIBC (15:47)
Intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (20:37)
Dispelling myths and misperceptions about cystectomy and counseling eligible patients (26:19)
Neoadjuvant and adjuvant therapy for MIBC (37:40)

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer (Companion Faculty Lecture) Oct 20, 2022

Show notes

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics:

Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00)
Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26)
Emerging data with novel agents and strategies for the management of UBC (14:52)
Case: A man in his mid 70s with a history of high-grade T1 disease who is not a good candidate for cystectomy (18:57)
Case: A man in his early 80s with high-grade T2 MIBC who is not a candidate for cystectomy or neoadjuvant chemotherapy (22:27)
Case: A woman in her late 50s with completely resected UBC with a strong preference for bladder-sparing treatment (24:43)

CME information and select publications

Myelodysplastic Syndromes | Exploring Current Considerations and Promising Investigational Approaches for Patients with Myelodysplastic Syndromes Oct 19, 2022

Show notes

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman, including the following topics:

Prologue: A vision for the future (0:00)
Classification and prognosis of myelodysplastic syndromes (MDS) (23:34)
Current management of lower-risk MDS (25:57)
Current management of higher-risk MDS (38:16)
MDS-Acute Myeloid Leukemia continuum and overlap: Venetoclax and other targeted therapy (46:38)

CME information and select publications

Small Cell Lung Cancer | Meet The Professor: Optimizing the Management of Small Cell Lung Cancer — Part 2 Oct 17, 2022

Show notes

Featuring perspectives from Dr Carl Gay, including the following topics:

Introduction: Journal Club with Carl M Gay, MD, PhD (0:00)
Case: A woman in her early 60s with extensive-stage small cell lung cancer (ES-SCLC) and a small residual lung mass after carboplatin/etoposide/atezolizumab — Kapisthalam (KS) Kumar, MD (19:15)
Case: A woman and heavy smoker in her early 70s who develops widespread ES-SCLC after chemotherapy/radiation therapy for limited-stage SCLC — Neil Morganstein, MD (24:24)
Case: A man in his mid 60s with ES-SCLC and disease progression after carboplatin/etoposide/atezolizumab with central nervous system metastases (FGFR1 gain, tumor mutational burden 11 mut/Mb) who receives lurbinectedin/radiation to the brain — Adam R Miller, MD (38:36)
Case: A man in his early 60s with progressive ES-SCLC s/p carboplatin/atezolizumab on lurbinectedin with dose adjustment — Rohit Gosain, MD (47:38)
Case: A woman and current smoker in her early 70s with ES-SCLC who receives dose-attenuated chemoimmunotherapy due to multiple comorbidities — Minesh Dinubhai Patel, MD (58:09)

CME information and select publications

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 5 Oct 13, 2022

Show notes

Featuring perspectives from Dr Stephanie Lheureux, including the following topics:

Prologue: Seminars in Cancer Biology (0:00)
Case: A woman in her mid 50s with Stage IVB BRCA wild-type, HR-proficient primary peritoneal cancer — Dana M Chase, MD (10:54)
Case: A woman in her mid 70s with recurrent platinum-sensitive peritoneal cancer (Lynch, VUS) and a gBRCA2 mutation— Karim ElSahwi, MD (32:33)
Case: A woman in her early 60s with ovarian cancer and prolonged pancytopenia after treatment with a PARP inhibitor — Joseph Martins, MD (38:51)
Case: A woman in her mid 60s with platinum-resistant recurrence of BRCA wild-type clear cell ovarian cancer after carboplatin/paclitaxel/bevacizumab and maintenance bevacizumab (homologous recombination deficiency [HRD] negative) — Neil Morganstein, MD (43:21)
Case: A woman in her early 60s with multiregimen-recurrent BRCA wild-type, HRD-negative metastatic ovarian cancer — Rahul Gosain, MD (47:44)
Case: A woman in her late 60s with recurrent platinum-resistant, BRCA wild-type, HR-proficient ovarian cancer after receiving paclitaxel/tumor treating fields on a clinical trial — Dr Chase (52:07)

CME information and select publications

Head and Neck and Thyroid Cancers | Meet The Professor: Optimizing the Management of Head and Neck and Thyroid Cancers Oct 11, 2022

Show notes

Featuring perspectives from Dr Robert Haddad, including the following topics:

ESMO 2022 (0:00)
Case: A man in his early 50s presents with metastatic anaplastic thyroid cancer — Ezra Cohen, MD (18:39)
Case: A man in his late 60s who has undergone immunotherapy for melanoma is diagnosed with Stage I (cN2 N1) p16-positive squamous cell carcinoma (SCC) of the left tonsil — Erik Rupard, MD (26:21)
Case: An Asian woman in her early 40s who has received cisplatin/radiation therapy and gemcitabine/cisplatin for locoregionally advanced nasopharyngeal cancer develops metastatic disease (PD-L1 CPS 10) — Dr Cohen (31:21)
Case: A man in his early 70s presents with recurrent and rapidly progressing HPV-negative metastatic head and neck cancer — Neil Morganstein, MD (38:55)
Case: A man in his late 50s who has undergone definitive radiation therapy and surgery for locally recurrent SCC of the head and neck presents with worsening shortness of breath — Mamta Choksi, MD (41:42)
Case: A man in his early 70s with a longstanding history of T-cell large granular lymphocytic leukemia presents with metastatic HPV-positive SCC of the left nostril (PD-L1-negative) — Spencer H Bachow, MD (44:50)
Case: A man in his late 50s presents with HPV-positive Stage III cancer of the base of the tongue — Dr Cohen (49:03)
Case: A man in his early 70s presents with metastatic anaplastic thyroid cancer (PD-L1-positive, mutations in TERT promoter, PT53 and MEN1) — Dr Rupard (52:00)
Case: A man in his early 60s presents with metastatic papillary thyroid cancer with a BRAF V600E mutation — Dr Cohen (56:16)

CME information and select publications

Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of Patients with Small Cell Lung Cancer (Companion Faculty Lecture) Oct 06, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Benjamin Levy, including the following topics:

Immune checkpoint inhibitors for treatment-naïve extensive-stage small cell lung cancer (ES-SCLC) (0:00)
Evaluating the role of lurbinectedin in therapy for SCLC (9:32)
Impact of trilaciclib on myelosuppression in patients with ES-SCLC (19:08)
Novel treatment strategies for patients with SCLC (22:14)

CME information and select publications